Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
Aste-Amézaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, Huang L, Vitelli S, Vo KT, Haytko P, Zhao JZ, Baleydier F, L'Heureux S, Wang H, Gordon WR, Thoryk E, Andrawes MB, Tiyanont K, Stegmaier K, Roti G, Ross KN, Franlin LL, Wang H, Wang F, Chastain M, Bett AJ, Audoly LP, Aster JC, Blacklow SC, Huber HE. Aste-Amézaga M, et al. Among authors: audoly lp. PLoS One. 2010 Feb 8;5(2):e9094. doi: 10.1371/journal.pone.0009094. PLoS One. 2010. PMID: 20161710 Free PMC article.
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.
Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L. Olwill SA, et al. Mol Cancer Ther. 2013 Nov;12(11):2459-71. doi: 10.1158/1535-7163.MCT-13-0318. Epub 2013 Sep 3. Mol Cancer Ther. 2013. PMID: 24002935
Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.
Hohlbaum AM, Gille H, Trentmann S, Kolodziejczyk M, Rattenstetter B, Laarakkers CM, Katzmann G, Christian HJ, Andersen N, Allersdorfer A, Olwill SA, Meibohm B, Audoly LP, Swinkels DW, van Swelm RPL. Hohlbaum AM, et al. Among authors: audoly lp. Br J Pharmacol. 2018 Apr;175(7):1054-1065. doi: 10.1111/bph.14143. Epub 2018 Feb 23. Br J Pharmacol. 2018. PMID: 29329501 Free PMC article.
In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.
Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA. Terwisscha van Scheltinga AG, et al. J Nucl Med. 2014 Apr;55(4):665-71. doi: 10.2967/jnumed.113.124941. Epub 2014 Mar 10. J Nucl Med. 2014. PMID: 24614223 Free article.
Endotrophin, a Key Marker and Driver for Fibroinflammatory Disease.
Henriksen K, Genovese F, Reese-Petersen A, Audoly LP, Sun K, Karsdal MA, Scherer PE. Henriksen K, et al. Among authors: audoly lp. Endocr Rev. 2024 May 7;45(3):361-378. doi: 10.1210/endrev/bnad036. Endocr Rev. 2024. PMID: 38091968 Review.
42 results